179688-14-3

Basic information

• Product Name: Benzoic acid, 3,4-bis(2-methoxyethoxy)-, methyl ester
• Synonyms: Benzoic acid, 3,4-bis(2-methoxyethoxy)-, methyl ester;Methyl 3,4-bis{[2-(Methyloxy)ethyl]oxy}benzoate;Methyl 3,4-bis(2-methoxyethoxy)benzoate
• CAS NO: 179688-14-3
• Molecular Formula: C₁₄H₂₀O₆
• Molecular Weight: 284.305
• Mol File: 179688-14-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzoic acid, 3,4-bis(2-methoxyethoxy)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3,4-bis(2-methoxyethoxy)-, methyl ester(179688-14-3)
• EPA Substance Registry System: Benzoic acid, 3,4-bis(2-methoxyethoxy)-, methyl ester(179688-14-3)

Safety Data

• Hazardous Substances Data: 179688-14-3(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 3,4-bis(2-methoxyethoxy)-, methyl ester is a chemical compound with the formula C17H22O7. It is a colorless to pale yellow liquid with a distinct odor. Benzoic acid, 3,4-bis(2-methoxyethoxy)-, methyl ester is commonly used as a solvent or plasticizer in the production of various materials, such as adhesives, polymers, and coatings. It is also utilized in the formulation of various personal care products and pharmaceuticals. Additionally, it can be employed as an intermediate in the synthesis of other organic compounds. Benzoic acid, 3,4-bis(2-methoxyethoxy)-, methyl ester may have some potential health and environmental hazards, and proper safety precautions should be taken when handling and using this chemical.

Upstream product

• 3943-89-3 Ethyl protocatechuate 
• 6482-24-2 2-Bromoethyl methyl ether 
• 67-56-1 methanol 
• 819813-71-3 3,4-bis(2-methoxyethoxy)-benzoic acid 
• 121-33-5 vanillin 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 80407-64-3 3,4-bis(2-methoxyethoxy)benzaldehyde 
• 99-50-3 3,4-Dihydroxybenzoic acid 
• 2150-43-8 3,4-dihydroxybenzoic acid methyl ester 

Downstream Products

• 179688-29-0 6,7-bis-(2-methoxyethoxy)-4(3H)quinazolinone 
• 882511-67-3 4-(4-iodo-phenoxy)-6,7-bis-(2-methoxy-ethoxy)-quinazoline 
• 882511-66-2 4-(3-iodo-phenoxy)-6,7-bis-(2-methoxy-ethoxy)-quinazoline 
• 882511-64-0 [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-iodo-phenyl)-amine 
• 882511-65-1 [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(4-iodo-phenyl)-amine 
• 882511-71-9 (3-{4-[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yloxy]-phenyl}-prop-2-ynyl)-dicyclohexyl-amine 
• 882511-70-8 (3-{3-[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yloxy]-phenyl}-prop-2-ynyl)-dicyclohexyl-amine 
• 882511-69-5 [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-[4-(3-dicyclohexylamino-prop-1-ynyl)-phenyl]-amine 
• 882511-68-4 [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-[3-(3-dicyclohexylamino-prop-1-ynyl)-phenyl]-amine 
• 183322-18-1 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline 
• 476168-17-9 2-amino-4,5-bis-(2-methoxyethoxy)-benzoic acid methyl ester 
• 838856-11-4 (3,4-bis{[2-(methyloxy)ethyl]oxy}phenyl)methanol 
• 819813-71-3 3,4-bis(2-methoxyethoxy)-benzoic acid 
• 838856-15-8 4-(3,4-bis{[2-(methyloxy)ethyl]oxy}phenyl)-3-methyl-1H-pyrazol-5-amine 

Relevant articles and documents

Preparation method of erlotinib intermediate

The invention relates to a preparation method of an erlotinib intermediate. The method concretely comprises the following steps: 1, dissolving vanillin in an organic solvent I, adding aluminum trichloride, adding pyridine in a dropwise manner, and reacting to obtain ELTA; 2, dissolving the ELTA in an organic solvent II, adding 2-chloroethylmethyl ether, potassium carbonate and a phase transfer catalyst, and reacting to obtain ELTB; 3, adding the ELTB to water, adding an alkali and potassium permanganate, and reacting to obtain ELTC; 4, adding concentrated sulfuric acid to methanol in a dropwise manner, adding the ELTC to the above reaction system, and reacting to obtain ELTD; 5, adding concentrated sulfuric acid to concentrated nitric acid in a dropwise manner, dissolving the ELTD in an organic solvent IV, adding a prepared mixed acid to the reaction system, and reacting to obtain ELTE; 6, adding the ELTE, iron powder and ammonium chloride to an organic solvent V, adding concentrated hydrochloric acid in a dropwise manner, and reacting to obtain ELTF; and 7, adding the ELTF, trimethyl orthoformate and ammonium acetate to an organic solvent VI, and reacting to obtain the erlotinib intermediate.

Synthesis and biological evaluation of allenic quinazolines using palladium-catalyzed hydride-transfer reaction

Allenic quinazolines 13a-h were designed as mimics of Tarceva, which is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and synthesized from the corresponding 4-(iodoanilino)quinazolines or 4-(iodophenoxy)quinazolines with N,N-dicyclohexylprop-2-ynylamine by the Sonogashira coupling followed by palladium-catalyzed hydride-transfer reaction. Cell growth inhibition of 13a-h toward A431, Kato III, SKBR3, and HepG2 was examined. Among the compounds synthesized, 13a showed a similar cell growth inhibition to Tarceva. Moreover, 13d and 13h exhibited a specific growth inhibition toward Kato III cells (IC50 = 12 and 4.7 μM, respectively), although a significant inhibition toward other three cell lines was not observed at a 100 μM concentration of compounds.

Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: Analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents

The syntheses and biological evaluations of 4-anilinoquinoline-3-carbonitrile analogues of the three clinical lead 4-anilinoquinazolines Iressa, Tarceva, and CI-1033 are described. The EGFR and HER-2 kinase inhibitory activities and the cell growth inhibition of the two series are compared with each other and with the clinical lead EKB-569. Similar activities are observed between these two series.